- PR Newswire•2 days ago
GAITHERSBURG, Md., Sept. 28, 2016 /PRNewswire/ -- GenVec, Inc. (GNVC), a clinical-stage gene delivery company, announced that Douglas E. Brough, Ph.D., the company's chief scientific officer, will present "Exploring the AdenoVerse™ Platform for New Advanced Cell and Gene Therapies", a brief review of GenVec's technology platform, at the 2016 Cell & Gene Meeting on the Mesa (CGMOM). This presentation will highlight new data that demonstrate the utility of select AdenoVerse vectors for efficient gene delivery to immune system cells, including T cells. GenVec believes that these vectors can be applied for therapeutic approaches focusing on genetically modified human primary T cells. GenVec has extensive expertise translating innovative product concepts from the laboratory to the clinic.
- American City Business Journals•last month
Gaithersburg-based GenVec Inc. is facing the threat of market delisting, but for now it has a bit more time to raise its share price. The gene delivery company (GNVC) first received a warning from the Nasdaq Stock Market in February because its share price was below the $1 minimum for 30 consecutive days.
- Capital Cube•2 months ago
Categories: Yahoo Finance Click here to see latest analysis GenVec, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of GenVec, Inc. – Emergent BioSolutions Inc., Pfizer Inc., Novartis AG Sponsored ADR, Merck & Co., Inc., Sangamo BioSciences, Inc., Astrazeneca PLC Sponsored ADR and Johnson & Johnson ... Read more (Read more...)
GenVec, Inc. (GNVC)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Ask||0.57 x 10000|
|Day's Range||0.45 - 0.51|
|52wk Range||0.35 - 3.69|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-1.37|
|Avg Vol (3m)||127,662|
|Dividend & Yield||N/A (N/A)|